"In vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging (MRS(I)) are unique, indispensable techniques for non-invasive metabolic imaging. Important areas where MRS(I) can make a difference are oncology and neurology, where metabolic changes due to, e.g., tumour formation, can be detected earlier and more sensitively than with morphological imaging modalities alone. Despite its huge proven potential, MRS(I) is not yet a routine clinical tool operated solely by clinicians. This requires reliable automation of complex procedures, strengthening standardisation and quality control. This in turn requires significant research progress and training of a new generation of scientists. Specifically, TRANSACT aims at:- Training 13 young scientists as future leaders in the field of MRS(I), capable of contributing with essential new developments such as spectral quality assurance criteria and standards, and optimal exploitation of complementarities between multi-modal magnetic resonance imaging modalities.- Pursuing research advances in theoretical and practical aspects of MRS, in particular experimental design by quantum mechanical simulation, data acquisition, data processing, data fusion and biomedical applications in oncology and neurology.- Establishing Europe as leader in the field within three sectors: academia, industry, clinic.TRANSACT links 10 academic and 4 industrial partners with complementary expertise in basic science, clinical research and information technology. Through a detailed training programme consisting of individual research projects, well-targeted secondments, scientific network-wide workshops, transferable skills courses, and individualized progress follow-up, TRANSACT will ensure a successful outcome in terms of career perspectives for the recruited researchers, continued collaboration between the partners and a more structured doctoral training in this field."